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Abstract: Mannheimia haemolytica is responsible for considerable economic losses to sheep, goats, and cattle and other livestock
industries in Egypt. This study aimed to evaluate the effectiveness of a newly developed gamma irradiation vaccine against Mannheimia
haemolytica in comparison to a formalin-killed vaccine. Three groups of rabbits were used in this study. Group 1 animals were inoculated
with 4 × 109 bacterial cells per dose of the formalin-killed vaccine. Group 2 was inoculated with 2 × 109 bacterial cells per dose of
gamma-irradiated vaccine. Group 3 (control group) was injected with 2 mL of sterile PBS. The vaccines were injected subcutaneously
into experimental animals twice with 3-week intervals between inoculations. Three weeks after the second vaccination dose, the animals
in all groups were infected with M. haemolytica twice with 1-week intervals between inoculations. Blood samples were collected weekly
after the first vaccination until one week after the second M. haemolytica infection challenge. ELISA results revealed that the gamma
irradiation vaccine developed in this study provided protective effects that reached high levels at the time of challenge. Furthermore, the
second dose of gamma irradiation vaccine could act as a booster dose resulting in increased antibody production.
Key words: Mannheimiosis, vaccine, gamma radiation, formalin-killed, ELISA

1. Introduction
Vaccination is aimed at inducing active immunity in an
individual so that subsequent contact with a pathogen
following natural infection induces a strong protective
immune response. Even though no vaccine is entirely safe
or completely effective, their use is strongly supported
by their benefit-to-risk ratio (1). Conventional vaccines
fall into one of three types: live, attenuated vaccines;
killed, inactivated vaccines; and toxoids. Live vaccines are
prepared from organisms that have no virulence in the
target animal. They are prepared from naturally occurring
(or induced) mutated organisms, or culture passages to
reduce their pathogenicity. Killed vaccines are prepared
from highly immunogenic strains of organisms that are
treated with chemicals that do not interfere significantly
with the conformation of their surface proteins, and
toxoid vaccines are based on antigenically altered toxins
that are secreted by the pathogen and produce the clinical
symptoms associated with the disease. In this case, the
vaccine does not prevent infection but protects against the
effects of the toxins produced by the pathogen (2,3).
* Correspondence: selnahta@yahoo.com

Many studies reported several disadvantages of these
types of vaccines. Live vaccines cannot be given safely to
immunosuppressed individuals and administration of live
attenuated vaccines to individuals with impaired immune
function can cause serious illness or death in the vaccine
recipient. The attenuated vaccine may also revert to its
virulent form and cause disease (1,3,4).
Vaccine development focuses on a variety of
technological initiatives and applied research, which
enhances and promotes improved systems and practices
for vaccine safety. Among the practical applications of
radiobiological techniques that may be of considerable
interest for public health is the use of ionizing radiation
in the preparation of vaccines. Vaccines developed by
irradiation have been tested and reported as strong
inducers for cellular and humoral immune response that
make this type of vaccine highly effective (5–7).
The objective of this study was to evaluate the
effectiveness of a gamma irradiation vaccine compared to
a formalin-killed vaccine against Mannheimia haemolytica
in three groups of experimental animals and two challenges.
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2. Materials and methods
2.1. Sample collection and bacterial isolation
Samples from both healthy and pneumonic lungs were
obtained from freshly slaughtered sheep of the Basateen
automated slaughter house (Cairo, Egypt). The samples
were collected in separate plastic bags, which were labeled
and kept cooled in an ice-chest until being transported to
the laboratory. The samples were cultured overnight at 37
°C in Erlenmeyer flasks containing 200 mL of brain/heart
infusion broth (gelatin peptone 10 g, sodium chloride 5 g,
beef/heart infusion 10 g, disodium phosphate 2.5 g, calf
brain infusion 7.5 g, dextrose 2 g, and distilled water up to
1 L; final pH 7.4 ± 0.2 at 25 °C, autoclaved).
Based on morphology under a microscopy, suspected
colonies were cultured on Tryptone Soya Agar (Oxoid)
with 10 g/L NaCl and 10 mL of sheep blood selective
medium for M. haemolytica and on MacConkey. The plates
were incubated aerobically and anaerobically at 37 °C for
24–72 h, followed by purification through subculturing.
The isolates were subjected to further identification using
Gram staining and biochemical reactions (8).
2.2. Molecular identification of M. haemolytica
Bacterial genomic DNA was extracted from colonies on a
plate using a Wizard genomic DNA isolation kit (#A1120,
Promega Corporation, USA). 16S rRNA gene sequencing
was used for molecular identification of M. haemolytica
(9). PCR amplification of the 16S rRNA gene was carried
out using forward primer 8F 5’ AGA GTT TGA TCC
TGG CTC AG and reverse primer U1492R 5’ GGT TAC
CTT GTT ACG ACT T, PCR green master mix (Promega
Corporation), and 0.2 µg of purified bacterial DNA per
reaction. PCR thermal cycling conditions consisted
of initial denaturation at 95 °C for 7 min for one cycle
followed by 35 cycles of denaturation at 95 °C for 1 min,
annealing at 50 °C for 1 min, and extension at 72 °C for
1 min. A final extension step was performed at 72 °C for
7 min (one cycle). PCR products were electrophoresed
on 1.5% agarose gel together with a 100-bp DNA ladder
(Promega Corporation) for molecular weight estimation.
2.3. Preparation of vaccines
2.3.1. Formalin-killed vaccine
The vaccine was prepared according to Selim et al. (10)
and Ruzauskas (11). A single colony of M. haemolytica
was inoculated into 5 mL of Tryptone Soya Broth and
incubated at 37 °C for 18–24 h in a shaking incubator.
After incubation, the broth culture was centrifuged at
6000 × g at 4 °C for 15 min. The supernatant was discarded
and the pellet of cells was washed twice with acetone and
thereafter twice with diethyl ether. The pellet was then
resuspended in 1% formalin saline. Tween 80 was added
to the suspension at a final concentration of 3%–4%. This
procedure was repeated three times with saline solution
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and the inactivated bacterial cells were resuspended to a
final concentration of 4 × 109 cells/mL.
2.3.2. Gamma irradiation vaccine
A single colony of M. haemolytica was inoculated into 5
mL of Tryptone Soya Broth and incubated at 37 °C for 18–
24 h in a shaking incubator. M. haemolytica was exposed
to different doses of gamma radiation ranging from 2
to 20 kGy. The process was achieved (under cooling) by
using a Co60 source (Russian Facility, Model Issledovatel).
Bactericidal activity of different radiation doses was
assessed by subcultivation of M. haemolytica cells on Soya
Tryptone Agar medium after irradiation. The optimum
was the lowest amount of radiation that was lethal to M.
haemolytica cells (12,13).
2.4. Animals
Four-week-old white New Zealand rabbits (Animal
Production Research Institute, New Zealand) were used in
experimental infection studies. The rabbits were barrierbred, unvaccinated, and free of a variety of pathogens.
Animals were allowed a 1-week period of acclimatization
following their arrival at the vivarium. The animals were
individually housed in stainless steel cages and slatted
bottoms did not contain bedding. The rabbits were allowed
ad libitum access to fresh tap water by water bottles and
were fed a balanced commercial feed.
2.5. Bacterial infection challenge
M. haemolytica was grown confluent on dextrose starch
agar plates overnight at 37 °C. The cells were harvested
in 0.01 M phosphate-buffered saline (PBS), centrifuged,
washed twice in PBS, and diluted to a final concentration
of 3.6 × 1010/mL. The animals in all groups were inoculated
subcutaneously with the challenge organism at a dose of
0.5 mL per rabbit, the challenge dose according to Lu and
Pakes (14).
2.6. Experimental design
The animals were classified into three groups and subjected
to treatment as follows:
Group 1 (formalin-killed vaccine, FKV) was vaccinated
subcutaneously with two doses of formalin-killed vaccine
with M. haemolytica at 4 × 109 bacterial cells/dose. The
second dose was given 3 weeks after the first dose.
Group 2 (gamma irradiation vaccine, GIV) was
vaccinated subcutaneously with gamma-irradiated M.
haemolytica (2 × 109 bacterial cells/dose). The second dose
was given 3 weeks after the first dose.
Group 3 (control group, CG) was injected
subcutaneously with 2 mL of sterile PBS and was kept as
the negative control group.
2.7. M. haemolytica infection challenge
Challenge with wild M. haemolytica (0.5 mL of 3.6 × 1010/
mL) was done twice for all experimental animals. The first
infection was 3 weeks after the second dose of vaccination.
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The second infection was given 1 week after the first
infection (0.5 mL of 3.6 × 1010/mL).
2.8. Sample collection for vaccine evaluations
Blood samples were collected at the beginning of every
week after the first dose of vaccination until 1 week after
the second infection. Collected samples were centrifuged
at 4500 × g for 10 min at 4 °C. Plasma samples were
transferred to 1.5-mL tubes and frozen at –20 °C until
used.
2.9. Evaluation of vaccine efficiency using enzyme linked
immune-sorbent assay (ELISA)
The antibody production was evaluated using optical
density (OD) as an indication of the efficiency of the tested
vaccines against M. haemolytica to generate an immune
response. Plasma samples were assayed for antibodies
against M. haemolytica by ELISA. The polystyrene
microtiter wells were coated with sonicated antigen, which
was prepared as follows: the bacterial cells were diluted
in bicarbonate buffer (pH 9.6) at an absorbance of 1.0
measured spectrophotometrically at 450 nm. Thereafter,
the suspension was sonicated for 15 min at 35% power
using a cell disrupter with a microtip-probe and diluted
(1:10) in carbonate-bicarbonate buffer (pH 9.6). Finally,
100 µL of the diluted bacterial antigen solution was added
to each well of a 96-well (flat-bottom) ELISA plate. The
plate was then incubated at 4 °C overnight. The plates were
washed 3 times with PBS (PH 7.4) containing 0.5% (v/v)
Tween 20 and then incubated for 30 min at 37 °C with
1% (w/v) bovine serum albumin (Sigma Chemical Co.,
St. Louis, MO, USA). Immediately before samples were
tested, wells were washed three times with PBS-Tween 20.
Based on preliminary assays, plasma samples were diluted
1:5 in PBS and incubated in duplicate PTE-coated wells
and uncoated wells (to control for nonspecific absorption)
for 1 h. Thereafter, the wells were washed with PBS-Tween
20, 100 µL of the diluted rabbit IgG heavy and light chain
antibody conjugated horseradish peroxidase (Bethyl
Laboratories Inc., USA; Cat. No. A120-101P) (1:10,000)
was added to all wells, and wells were incubated at 37 °C for
1 h. Next, 100 µL of substrate 3,3,5,5-tetramethylbenzidine
solution (Bethyl Laboratories; Cat. No. E102) was added
and kept for 15 min at 37 °C, after which a color change
was observed in the wells. The reaction was stopped by the
addition of 25 µL of sulfuric acid (95%–97%) per well. The
plates were read at 405 nm spectrophotometrically using
an ELISA reader (BioTek ELX800, with software Gen5
2.00).
2.10. Statistical analysis
The results of OD values were analyzed using the arithmetic
mean, the standard deviation, and ANOVA and post hoc
multiple comparison tests according to Pipkin (15).

3. Results
3.1. Identification of M. haemolytica
The PCR-amplified product of the M. haemolytica 16S
rRNA gene was visualized at 1.5 kbp. BLAST analysis of the
M. haemolytica 16S rRNA gene sequence indicated that the
isolated M. haemolytica sequence showed similar identity
to the Mannheimia haemolytica D174 complete genome
in the region of the 16S ribosomal DNA sequence (NCBI
Sequence ID: gb|CP006574.1|). This result confirmed that
the isolated microorganism in this study’s samples was M.
haemolytica.
3.2. Evaluation of the results between control and
vaccinated groups
The OD values of the GIV group showed significant
difference at 3 weeks after the first vaccination dose,
while the OD values of the FKV group showed significant
difference at the first and second weeks and nonsignificant
difference at the third week compared to the control
group. After the second vaccination dose, the OD value of
the FKV group showed a significant difference at the first
week while it was nonsignificant at the second and third
weeks compared to the control group. The OD value of
the GIV group showed nonsignificant difference only at
the second week of the second vaccination compared to
the control group. The mean OD value of the two vaccines
showed a significant difference after the first and second
vaccinations compared to the mean OD value of the
control group (Figure).
3.3. Evaluation of the results between the FKV and GIV
inoculation groups
The results of OD values of the FKV and GIV groups are
shown in Table 1. The differences between OD values in
the 3 weeks after the first vaccination dose varied between
the two vaccines. At the first and second weeks, the OD
values of the FKV and GIV groups had a nonsignificant
difference, while at the third week the OD values between
the FKV and GIV groups was significantly different.
The estimated OD values at the second vaccination dose
between the GIV and FKV groups were significantly
different at the first and third weeks (1.426, 1.316 and
1.265, 1.129, respectively), while they were nonsignificant
at the second week (1.263 and 1.263, respectively). The
mean of OD values between the two vaccinated groups
after the first vaccination dose was nonsignificant, while
the mean of OD values of the second vaccination dose
showed a significant difference between the GIV and FKV
groups (Figure).
3.4. Challenge results
The mean values of OD in various challenge treatments are
illustrated in Table 2. The mean value of OD in the FKV
and GIV groups was significantly different compared to
the control group after the first and second M. haemolytica
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Figure. The mean of OD values at the first and second vaccination doses in FKV, GIV, and CG groups.
Table 1. The OD values in all experimental groups.

Vaccine treatment/time/dose

D1 (first dose)

D2 (second dose)

W1

W2

W3

Mean

W1

W2

W3

Mean

FKV

1.423

1.406

1.185

1.338

1.265

1.263

1.129

1.219

GIV

1.497

1.417

1.007

1.307

1.426

1.263

1.316

1.34

CG

1.061

1.196

1.125

1.127

1.152

1.168

1.168

1.163

LSD dose × time1

0.108608

LSD type × time

0.133017

Only LSD values for significant interactions are shown.

1

Table 2. The OD values in all experimental groups after challenge.
Challenged vaccine type/challenge dose

FKV

GIV

CG

CD1

1.409

1.633

0.870

CD2

1.468

1.571

1.276

LSD 5%

0.102061154

infections. The mean values of OD in the two challenges
showed that the OD of the GIV group was highly significant
compared to the FKV group.
4. Discussion
Pneumonic mannheimiosis caused by M. haemolytica is
one of the major problems in sheep, goats, and cattle. It
is responsible for considerable economic losses in these
animals and other livestock industries in many parts of the
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world (16). In Egypt, M. haemolytica is found in the upper
respiratory tract of healthy animals as well as in diseased
animals. M. haemolytica was also recorded with frequent
association with the bovine respiratory disease complex,
causing severe pneumonic damage in Egyptian cattle,
sheep, and goats (16,17). A vaccine that has the potential
to provide protection against M. haemolytica from a
local strain is needed in order to combat and control the
disease in Egyptian livestock. Therefore, this study aimed
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to investigate the effectiveness of two different candidate
vaccines against M. haemolytica.
Evaluation of the results obtained for the ELISA assay
between gamma-irradiated vaccine and the conventional
formalin-killed vaccine revealed that after the first vaccination
dose the ELISA assay of the two vaccines was nonsignificant
at the first and second weeks. At the third week the OD
value of the FKV and GIV groups was significantly different
(Table 1). The results suggested that animals injected with the
gamma-irradiated vaccine were able to avoid the vaccination’s
side effects and their bodies maintained their normal states,
which could support the animal body’s functions to perform
its full production process.
After the second vaccination dose, a significant
difference was observed between the GIV and FKV groups
at the first and third weeks (1.426, 1.316 and 1.26, 1.129,
respectively), while it was nonsignificant at the second
week (1.26 and 1.2, respectively) (Table 1). The same
observation was reported by Confer et al. (18) and Sun
(19). They recorded a decrease of specific antibody against
whole-cell M. haemolytica antigens in vaccinated animals
at day 14 after vaccination and an increase at day 21, but
the average response still remained higher than that of
control animals.
Regarding the results of the GIV group, after the second
dose of vaccine inoculation the amount of antibodies was
the same as after the first inoculation. This indicated that
the second dose of gamma-irradiated vaccine could act
as a booster dose stimulating antibody production and
thus facilitate a higher immune response upon exposure
to M. haemolytica. This advantage does not exist with
the formalin-killed vaccine. The results of the second

dose inoculation related to antibody production are in
agreement with previous studies on irradiation vaccines
against Schistosoma mansoni, Listeria monocytogenes,
malaria, and Brucella (5,6,20,21).
The strength of vaccine immunization has been
evaluated with wild M. haemolytica infection. The
experiment was carried out by infecting rabbits with M.
haemolytica 3 weeks after the second vaccination dose
twice with a 1-week interval. Each challenge dose was
0.5 mL of 3.6 × 1010/mL. The present study applied the
experiment using rabbits as an model animal, which are
naturally not susceptible to infection by M. haemolytica.
This gave the chance to compare the effectiveness of
vaccine treatment on immunity of treated and nontreated
animals after challenge (22). The results proved that the
OD of the GIV group was highly significant compared to
the control and FKV groups (Table 2). This result suggests
that the gamma-irradiated vaccine could provide high
immunity against mannheimiosis.
The present study indicates that the newly developed
gamma irradiation vaccine provided protective effects
against M. haemolytica infection in rabbits that reached
high levels at the time of challenge. The second dose
of gamma irradiation vaccine could act as a booster
dose resulting in an increase in the amount of antibody
production.
Acknowledgment
The authors thank the Deanship of Scientific Research and
the Research Center, College of Food and Agricultural
Sciences, King Saud University, Kingdom of Saudi Arabia,
for supporting this work.

References
1.

Meeusen EN, Walker J, Peters A, Pastoret P, Jungersen G.
Current status of veterinary vaccines. Clin Microbiol Rev 2007;
20: 489–510.

2.

Curtiss R. Bacterial infectious disease control by vaccine
development. J Clin Invest 2002; 110: 1061–1066.

3.

Plotkin S. Vaccines, vaccination, and vaccinology. J Infect Dis
2003; 187: 1347–1359.

4.

Plotkin S. Correlates of vaccine-induced immunity. Clin Infect
Dis 2008; 47: 401–409.

5.

Eberl M, Langerman J, Frost P, Vervenne R, Van dam G, Deelder
A, Thomas A, Coulson P, Wilson R. Cellular and humoral
immune responses and protection against schistosomes
induced by a radiation-attenuated vaccine in chimpanzees.
Infect Immun 2001; 69: 5352–5362.

6.

Datta S, Okamoto S, Hayashi T, Shin S, Mihajlov I, Fermin A,
Guiney D, Fierer J, Raz E. Vaccination with irradiated Listeria
induces protective T cell immunity. Immunity 2006; 25: 143–
152.

7.

Zorgi NE, Costa A, Galisteo AJ, Nanci N, de Andrade HF.
Humoral responses and immune protection in mice immunized
with irradiated T. gondii tachyzoites and challenged with three
genetically distinct strains of T. gondii. Immunol Lett 2011;
138: 187–196.

8.

MacFaddin JF. Biochemical Tests for Identification of Medical
Bacteria. 3rd ed. Philadelphia, PA, USA: Lippincott Williams
and Wilkins; 2000.

9.

James G. Universal bacterial identification by PCR and DNA
sequencing of 16S rRNA gene. In: Schuller M, Sloots TP,
James GS, Halliday CL, Carter IWJ, editors. PCR for Clinical
Microbiology. Amsterdam, the Netherlands: Springer; 2010.
pp. 209–214.

10.

Selim SA, Ghoneim ME, Mohamed KF. Vaccinal efficacy
of genetically inactivated phospholipase D against caseous
lymphadenitis in small ruminants. International Journal of
Microbiological Research 2010; 1: 129–136.

223

AHMED et al. / Turk J Vet Anim Sci
11.

Ruzauskas M. Development and assay of inactivated Pasteurella
vaccine for rabbits. Biologija 2005; 2: 35–39.

12.

Aquino S, Ferreira F, Ribeiro DHB, Corrêa B, Greiner R,
Villavicencio ALCH. Evaluation of viability of Aspergillus
flavus and aflatoxins degradation in irradiated samples of
maize. Braz J Microbiol 2005; 36: 352–356.

13.

Abo-State M, Hammad A, Swelim M, Gannam R. Enhanced
production of cellulase (S) by Aspergillus spp. isolated from
agriculture wastes by solid state fermentation. AmericanEurasian Journal of Agriculture & Environmental Science
2010; 8: 402–410.

14.

Lu YS, Pakes SP. Protection of rabbits against experimental
pasteurellosis by a streptomycin-dependent Pasteurella
multocida serotype 3: a live mutant vaccine. Infect Immun
1981; 34: 1018–1024.

15.

Pipkin B. Medical Statistics Made Easy. 5th ed. New York, NY,
USA: Churchill Livingstone; 1984.

16.

Sabri MY, Shahrom-Salisi M, Emikpe BO. Comparison prior
and post vaccination of inactivated recombinant vaccine
against mannheimiosis in Boer goats farm in Sabah. Journal of
Vaccines & Vaccination 2013; 4: 173.

17.

Kaoud H, El-Dahshan A, Zaki M, Shimaa A. Occurrence of
Mannheimia haemolytica and Pasteurella trehalosi among
ruminants in Egypt. New York Science Journal 2010; 3: 135–
141.

224

18.

Confer AW, Ayalew S, Montelongo M, Step DL, Wray JH,
Hansen RD, Panciera RJ. Immunity of cattle following
vaccination with a Mannheimia haemolytica chimeric PlpE–
LKT (SAC89) protein. Vaccine 2009; 27: 1771–1776.

19.

Sun T. Evaluation of a vaccine against Mannheimia haemolytica
and Pasteurella multocida in sheep. Honors Thesis, Cornell
University, Ithaca, NY, USA, 2009.

20.

Syaifudin M, Tetriana D, Darlina D, Nurhayati S. The feasibility
of gamma irradiation for developing malaria vaccine. Atom
Indonesia 2011; 37: 91–101.

21.

Dabral N, Moreno-Lafont M, Sriranganathan N, Vemulapalli
R. Oral immunization of mice with gamma-irradiated Brucella
neotomae induces protection against intraperitoneal and
intranasal challenge with virulent B. abortus 2308. PLoS One
2014; 9: 1–12.

22.

Petre J, Pizza M, Nencioni ML, Podda A, De Magistris MT,
Rappuoli R. The reaction of bacterial toxins with formaldehyde
and its use for antigen stabilization. Dev Biol Stand 1996; 87:
125–134.

